Categories Tumor Testing
Relevance: Medium-High
Most relevant for: People with node-negative, ER-positive breast cancer
Study: Some women with early-stage breast cancer forego chemotherapy
A research study named the “Trial Assigning Individualized Options for Treatment” (TAILORx) asked whether chemotherapy is beneficial for women who have mid-range Oncotype DX tumor recurrence scores. This trial — the largest breast cancer treatment trial ever conducted— showed that endocrine therapy alone was as effective as endocrine therapy plus chemotherapy in women with certain types of early-stage breast cancer. The results of this trial are expected to be immediately practice changing (7/20/18)
READ MORE ›
Relevance: Medium-High
Most relevant for: Women diagnosed with ER-positive, Her2-negative early-stage breast cancer with 0-3 positive nodes
Guideline: Can MammaPrint guide treatment decisions?
The American Society of Clinical Oncology (ASCO) updated its guidelines for MammaPrint, a genomic tumor test that guides treatment decisions for patients with early-stage invasive breast cancer. The update was based on results from the MINDACT study (11/16/17).
READ MORE ›
Relevance: Medium-Low
Most relevant for: Patients with ER+ breast cancer
Study: Common genetic change found in some tumors of patients who relapse after aromatase inhibitor treatment
About one in five people diagnosed with estrogen receptor-positive (ER+) breast cancer relapse within 10 years after treatment. Researchers and health care providers do not know why this happens. This early research aims to identify a genetic change in the tumor that may cause relapse, but more studies are needed to understand why patients relapse and who is at risk. (5/3/17)
READ MORE ›
Relevance: Medium
Most relevant for: People diagnosed with advanced cancer
Article: A cancer patient’s tumor is genetically profiled—how does that info help treatment?
Jessica Wapner's Scientific American article explores the difficulties of making the vast amount of information acquired from tumor gene tests useful to patients and physicians. (9/20/16). Update: THIS INFORMATION HAS BEEN UPDATED. In late 2017, the FDA approved two separate tumor profiling tests to help guide treatment choices. The FoundationOne CDx (F1CDx) genomic test has been approved to test for 15 different targeted therapies used to treat five types of cancer, including ovarian, colorectal, lung, breast and melanoma. The FDA also approved the MSK-IMPACT and developed for use by Memorial Sloan Kettering Cancer Center (MSKCC) to scan tumor samples for 468 different cancer-associated mutations or alterations.
READ MORE ›
Relevance: Medium
Most relevant for: People diagnosed with breast cancer that is "high-grade" or aggressive
Study: Cellular diversity in tumors may predict survival for some types of breast cancer
Some tumors are made up of many different types of cells, while others contain generally the same cell type. This study found that among people with high-grade breast cancer, those who have tumors made up of many different cell types have a lower 10-year survival rate than people with tumors containing only a single type of cells. This research is an early step towards developing a new test that can help physicians identify cancers that need more aggressive treatment, but more research is needed before it is ready for clinical use. (4/26/16)
READ MORE ›